p brk Search Results


anti-phospho-brk (tyr351) [p-brk (tyr351  (YenZym Inc)
90
YenZym Inc anti-phospho-brk (tyr351) [p-brk (tyr351
( a–c ) Immunohistochemical staining using antibodies against phospho-BRK <t>(Tyr351)</t> (a), phospho-HIF1α (Tyr565) (b), or phospho-GPNMB (Tyr525) (c) in human breast cancer tissues. Upper panel: representative image. Scale bars, 100µm; Lower panel: statistics analysis based on non-TNBC tissues ( n =5) vs . TNBC tissues ( n =40) and non-Metastasis (TnN0M0) TNBC ( n =27) vs . Metastasis (TnN>0M>0) breast tissues ( n =13) (median, two-way ANOVA). ( d–f ) Upper panel: statistical analysis of immunohistochemical staining using antibodies against phospho-BRK (Tyr351) (d), phospho-HIF1α (Tyr565) (e) or phospho-GPNMB (Tyr525) (f) in human breast cancer tissues including TNBC ( n =10), ER−/PR−/HER2+ ( n =7), ER+/PR+/HER2- ( n =18), and ER+/PR+/HER2+ ( n =2) (median, two-way ANOVA). Lower panel: Pearson’s correlation analysis comparing staining density between LINK-A expression and phospho-BRK (Tyr351) (d), phospho-HIF1α (Tyr565) (e), or phospho-GPNMB (Tyr525) (f) within the TNBC group ( n =10 tissue samples, Fisher’s exact test). ( g–i ) Kaplan-Meier survival analysis of phosphor-BRK (Tyr351) (g), phosphor-HIF1α (Tyr565) (h), and phospho-GPNMB (Tyr525) (i) status in breast cancer patients ( n =160, Gehan-Breslow test).
Anti Phospho Brk (Tyr351) [P Brk (Tyr351, supplied by YenZym Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-phospho-brk (tyr351) [p-brk (tyr351/product/YenZym Inc
Average 90 stars, based on 1 article reviews
anti-phospho-brk (tyr351) [p-brk (tyr351 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


( a–c ) Immunohistochemical staining using antibodies against phospho-BRK (Tyr351) (a), phospho-HIF1α (Tyr565) (b), or phospho-GPNMB (Tyr525) (c) in human breast cancer tissues. Upper panel: representative image. Scale bars, 100µm; Lower panel: statistics analysis based on non-TNBC tissues ( n =5) vs . TNBC tissues ( n =40) and non-Metastasis (TnN0M0) TNBC ( n =27) vs . Metastasis (TnN>0M>0) breast tissues ( n =13) (median, two-way ANOVA). ( d–f ) Upper panel: statistical analysis of immunohistochemical staining using antibodies against phospho-BRK (Tyr351) (d), phospho-HIF1α (Tyr565) (e) or phospho-GPNMB (Tyr525) (f) in human breast cancer tissues including TNBC ( n =10), ER−/PR−/HER2+ ( n =7), ER+/PR+/HER2- ( n =18), and ER+/PR+/HER2+ ( n =2) (median, two-way ANOVA). Lower panel: Pearson’s correlation analysis comparing staining density between LINK-A expression and phospho-BRK (Tyr351) (d), phospho-HIF1α (Tyr565) (e), or phospho-GPNMB (Tyr525) (f) within the TNBC group ( n =10 tissue samples, Fisher’s exact test). ( g–i ) Kaplan-Meier survival analysis of phosphor-BRK (Tyr351) (g), phosphor-HIF1α (Tyr565) (h), and phospho-GPNMB (Tyr525) (i) status in breast cancer patients ( n =160, Gehan-Breslow test).

Journal: Nature cell biology

Article Title: The LINK-A lncRNA Activates Normoxic HIF1α Signaling in Triple-negative Breast Cancer

doi: 10.1038/ncb3295

Figure Lengend Snippet: ( a–c ) Immunohistochemical staining using antibodies against phospho-BRK (Tyr351) (a), phospho-HIF1α (Tyr565) (b), or phospho-GPNMB (Tyr525) (c) in human breast cancer tissues. Upper panel: representative image. Scale bars, 100µm; Lower panel: statistics analysis based on non-TNBC tissues ( n =5) vs . TNBC tissues ( n =40) and non-Metastasis (TnN0M0) TNBC ( n =27) vs . Metastasis (TnN>0M>0) breast tissues ( n =13) (median, two-way ANOVA). ( d–f ) Upper panel: statistical analysis of immunohistochemical staining using antibodies against phospho-BRK (Tyr351) (d), phospho-HIF1α (Tyr565) (e) or phospho-GPNMB (Tyr525) (f) in human breast cancer tissues including TNBC ( n =10), ER−/PR−/HER2+ ( n =7), ER+/PR+/HER2- ( n =18), and ER+/PR+/HER2+ ( n =2) (median, two-way ANOVA). Lower panel: Pearson’s correlation analysis comparing staining density between LINK-A expression and phospho-BRK (Tyr351) (d), phospho-HIF1α (Tyr565) (e), or phospho-GPNMB (Tyr525) (f) within the TNBC group ( n =10 tissue samples, Fisher’s exact test). ( g–i ) Kaplan-Meier survival analysis of phosphor-BRK (Tyr351) (g), phosphor-HIF1α (Tyr565) (h), and phospho-GPNMB (Tyr525) (i) status in breast cancer patients ( n =160, Gehan-Breslow test).

Article Snippet: Cell Signaling Technology : anti-EGFR (D38B1) rabbit mAb (4267), anti-GPNMB (E1Y7J) rabbit mAb (13251), anti-LRRK2 (5559), anti-phospho-EGFR (Tyr845) (D63B4) rabbit mAb (6963), anti-phospho-EGFR (Tyr992) (2235), anti-phospho-EGFR (Tyr1045) (2237), anti-phospho-EGFR (Tyr1068) (D7A5) rabbit mAb (3777), anti-phospho-EGFR (Tyr1148) (4404), anti-phospho-EGFR (Tyr1173) (53A5) rabbit mAb (4407), anti-hydroxy-HIF1α (Pro564) (D43B5) rabbit mAb (3434), anti-PHD2 (3293), anti-VHL (2738), anti-LRRK2 (5559), anti-EGFR (D38B1) rabbit mAb (Alexa Fluor ® 555 Conjugate) (5108), anti-GST tag (26H1) mouse mAb (2624), anti-His tag (2365) and anti-eIF4B (3592); Santa Cruz Biotechnology : anti-FIH (H-299) (sc-48813), anti-HA (Y-11) (sc-805), anti-BRK (C-18) (sc-1118), anti-GAPDH (6C5) mouse mAb (sc-32233) and anti-HIF1α (28b) mouse mAb (sc-13515); Millipore : anti-phosphotyrosine (4G10) Platinum mouse mAb (05-1050X), anti-Myc tag (4A6) mouse mAb (05-724) and anti-eIF4B (ABS281); Thermo Scientific : anti-EGFR (Ab-13) mouse mAb (MS-609); Sigma-Aldrich : anti-FLAG tag (M2) mouse mAb (F3165); Active Motif : anti-p300 (NM11) mouse mAb (61402); Novus Biologicals : anti-HIF1α (NB100-134); Life Technologies : anti-phosphoserine (Poly-Z-PS1); YenZym Antibodies, LLC : anti-phospho-GPNMB (Tyr525) [p-GPNMB (Tyr525)], anti-phospho-BRK (Tyr351) [p-BRK (Tyr351)], anti-phospho-HIF1α (Tyr565) [p-HIF1α (Tyr565)], and anti-phospho-HIF1α (Ser797) [p-HIF1α (Ser797)].

Techniques: Immunohistochemical staining, Staining, Expressing